News

Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program and Expand Use of Innovative Dendritic Cell Platform for Studies in Other Indications Recent Clinical Data for Dubodencel (DOC1021) in Glioblastoma Drive Financing with Backing from Baylor College of Medicine and The Brain Tumor Investment Fund Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced the closing of a $20 million private placement of Simple Agreements for Future Equity (SAFE) to […] May 30, 2025

Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the closing of an oversubscribed $52 million Series B financing round. The funds will support […] May 15, 2025

Alpheus Medical Publishes Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the publication of a study in the Journal of Neuro-Oncology showcasing its proprietary SDT treatment in three patients with newly diagnosed glioblastomas that were not candidates for gross total tumor resection. The study reported no adverse […] February 26, 2025

MimiVax Announces Positive Interim Analysis in Ongoing SurVaxM Clinical Trial -Ongoing clinical trial of SurVaxM in glioblastoma [SURVIVE] has successfully progressed following an interim analysis of trial data -The clinical trial is designed to evaluate the safety, efficacy, and overall benefit of SurVaxM in patients with newly diagnosed glioblastoma who receive standard-of-care treatment combined with SurVaxM -The fully enrolled Phase 2b SURVIVE study will continue as planned […] February 13, 2025

Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, and EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, are pleased to announce initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the […] January 30, 2025